Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 M4\LeGZ2dmO2aX;uJGF{e2G7 MmrpNkDPxE1? NIH4eo4yKGh? Mo[2bY5pcWKrdIOgeIhmKExvRF;QRUApOjEEoN88UUkucW6mdXPl[EB1emGwc3nlcpQhTVKNMT:yJJBpd3OyaH;yfYxifGmxbtMg M2Lkc|I3OzZ|MUmx
C2C12 MkOxSpVv[3Srb36gRZN{[Xl? NX;ZSHFVOcLizsznM41t Mo[xNeKhcA>? MX\hZo9tcXOqZYOgZ5l1d2urbnWgdoVt\WG|ZTDmdo9uKEN{Q{GyJI16d3S3YnXz NHvJU2ozPjJ7MUK3PS=>
MEFs WT MmfTSpVv[3Srb36gRZN{[Xl? MUi1xsDPxE1? M3ryOVIxKG2rbh?= MlfiZ4F2e2W|IILld4ll\W62IHXufplu\XNic4XjbEBieyCQQVfUMWdHWCxidH:g[Iln\nW|ZTDiZYNsKHSxIITo[UBGWg>? MWSyOlE6PjB{Mx?=
MEFs VAMP7 KO M{LOTmZ2dmO2aX;uJGF{e2G7 M{P6NFXDqM7:TR?= M1K4[|IxKG2rbh?= MY\jZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT NYniZ4N1OjZzOU[wNlM>
SMCs MVrGeY5kfGmxbjDBd5NigQ>? MkjZNVDDqML3Zz;tcC=> M2\FdVAuOTJiaB?= NX;KWnZrTE2VTx?= MYHzbI94eyCjIITy[Y5lKHSxd3Hy[JMh[SCqaXfo[ZIh[2:wY3XueJJifGmxbjDv[kB1cGViRWKvV3IhdmW2d3;yb{BqdiC2aHWgdIVzcW63Y3zlZZIh[XKnYdMg NY\yfXN7OjZzN{KwPFA>
SMCs M{DtdmZ2dmO2aX;uJGF{e2G7 MmLENVDDqML3Zz;tcC=> NW\rO5FlOC1zMjDo NIGzSYhFVVOR NXjSfYZJ[2G3c3XzJIEhfHKjboPp[Y51KEOjMjxCpJJmdGWjc3Wg[pJwdSC2aHWgSXIwW1MEoB?= M4rWeVI3OTd{MEiw
HEMC-1 NYrEdohnTnWwY4Tpc44hSXO|YYm= MY[wMlHDqML3Zz;tcC=> M2\EZ|I1yqCq MWLjZZV{\XNiYTDobYdp\XJiaX7obYJqfG:{eTDl[oZm[3Rib36g[Zhw[3m2b4Ppd{B1cGGwIH7vZ49l[XqxbHW= Mle4NlU6PzJ5NUm=
HUVEC NH\vWWNHfW6ldHnvckBCe3OjeR?= M4P1OlExyqEQvF2= MnrnNeKhcA>? NYH0Z|BnTE2VTx?= MnzxZYJwdGm|aHXzJIh6eG:6aXGtbY5lfWOnZDDy[Yxm[XOnIH;mJGFVWCCocn;tJIFxcWOjbDDhcoQh[mG|b3zheIVz[Wxic4Xy[oFk\XN? MX6yOVk2Pjl6OB?=
HUVEC NG\0dFFHfW6ldHnvckBCe3OjeR?= NV\EZ|Q{OTEEoN88US=> M1PFe|HDqGh? MmmwSG1UVw>? MWLpcoNz\WG|ZYRCpJRp\SCwdX3i[ZIh[W6mIHnueIVve2m2eTDv[kBndHWxcnXzZ4VvfCCjcnXhd{Bme3CnY3nhcIx6KGmwIIDldolvfWOuZXHyJJNx[WOn M365U|I2QTV4OUi4
Caco-2 MlG1SpVv[3Srb36gRZN{[Xl? NWfscHBuOi53IN88US=> MnXvN|AhdWmw NYfqc|FF[XS2ZX71ZZRmeyC2aHWgWGdHNc7{MT3t[YRq[XSnZDDpcoNz\WG|ZTDpckBUTVKWIH\1coN1cW:w MVOyOVk2PDl|MR?=
NRK M17rOmZ2dmO2aX;uJGF{e2G7 MVSyNFDjiIWwZz;tcC=> NV;lS5h6POLChXi= MYXEUXNQ NE\6NGdz\XOldXXzJI1qfG:2aXOgdJJw\3Knc4Ppc44> NIfwUnMzPTl2OEW4Oi=>
HeLa NV;wTHpFTnWwY4Tpc44hSXO|YYm= NVrHd4ZzOjBy4pEFcocwdWx? M1O4dlMhcA>? NU\ke2UxTE2VTx?= MkPQbY5lfWOnczD0bIUh[XK2aX\pZ4lidCCkcnXhb{12eCCxZjD0bIUhT2:uZ3mgZ49ueGyneB?= M3TaTVI2QTR6NUi2
COS M1Gwc2Z2dmO2aX;uJGF{e2G7 MVGxJO69\y:vbB?= MlSwN{Bp NHrnZpRkd22ybHX0[Yx6KGSrc4DldpNmeyC2aHWgRXAuOSC|aXfuZYzDqA>? NI\OR|EzPTlzNUmwNC=>
DF1  M324c2Z2dmO2aX;uJGF{e2G7 NEHiWnMyyqEQvF5CpC=> NITjU5Y1QCCq NE\CUIpFVVOR MnL1[Il{eGW{c3XzxsB1cGViZYjv[4Vvd3W|IFPTS4FtVkGlVEKgdJJwfGWrbh?= MYqyOVgxPzB3NB?=
nHDFs  MW\GeY5kfGmxbjDBd5NigQ>? MU[xxsDPxE4EoB?= MoDRNuKhcA>? Mkf1dJJmfmWwdIOgeIhmKGG|c3XtZox6KG:oIHP5eI9{d2yrYzDjc4F1KHC{b4TlbY5{KG:wdH:gS49t\2libXXtZpJidmW| M4nCbVI2Pzd{NkG2
FRT  M4DId2Z2dmO2aX;uJGF{e2G7 MUm1JO69\y:vbB?= NYnLb4NPOsLiaB?= MWnicI9kc3NidILh[oZq[2urbnegeIhzd3WpaDD0bIUhT2:uZ3mgZ49ueGyneDDifUBqdmirYnn0bY5oKEWULYTvMWdwdGerIITyZY5{eG:{dB?= M{izT|I2PzZ5MUG1
FRT  NG\VUHVHfW6ldHnvckBCe3OjeR?= NIPpRm02KM7:Zz;tcC=> NIPmVHYzyqCq NWjmVlRDeHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJINt\WG4ZXSg{tEhe3WkdX7peJMhf2inbjDbUoEsZWoEoIfhd{Bz\WS3Y3Xk M1;W[FI2PzZ5MUG1
HepG2  NXH0[IJvTnWwY4Tpc44hSXO|YYm= MlHnNgKBkcL3TdMg NFr3TIwzPCCq NX\ke3ZsTE2VTx?= M4r3eYRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiUGjSJI1TVkF? M4f3ZlI2PjF4NUm3
SMCs MYrGeY5kfGmxbjDBd5NigQ>? MWCx{txoN22O M3L2VVMhcA>? NYrKTnA1[WOldX31cIF1\XNiQ17QXVIheHKxdHXpckBqdiC2aHWgSXIh[2:vcHHyeI1mdnRiYX7kJI5wKGyxbnfldkBkdy2ub3PhcIl7\WRid3n0bEB1cGViR3;s[4khdWG{a3XyxsA> MlnnNlU2QDl2MkW=
OB-6 MmXERZBweHSxc3nzJGF{e2G7 MYiyMlfDqM7:TR?= M1W2XVQ5KGh? M1u3bIlv\HWlZYOgZZBweHSxc3nz Ml7vNlU2OzJ2OEC=
iPSC-CMs  MUPGeY5kfGmxbjDBd5NigQ>? MkDOOVAxKG6pL33s NH7NU|U1QCCq NILGcnpqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kB1cGViaHnnbIVzKG2xYnnsbZR6KEyDTWDzJIF1KHSqZTDjc5N1KG:oIITo[UBtd3encjDtc4JqdGm2eTDzdIVkcWW| MnXyNlU1QDh4Nk[=
SP-Nluc M4nCS2Z2dmO2aX;uJGF{e2G7 M4H0b|UhdWdxbVy= MWO2JIg> MW\EUXNQyqB? M1;H[4NifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> NFHmXZgzPTN7Mkm5PC=>
PEXEL-Nluc NUT2VJJzTnWwY4Tpc44hSXO|YYm= M4\zWlUhdWdxbVy= M2rieFYhcA>? MX;EUXNQyqB? NV62[|d5[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? MkO2NlU{QTJ7OUi=
H1299 NYS4bHBwTnWwY4Tpc44hSXO|YYm= MnKzNVAh|rypL33s M3rrRlI1KGh? M{DJ[olv\HWlZYOgZZV1d3CqYXf5xsA> NYH4R5k2OjV|OEi5O|A>
MDA-MB-231 M2f6bGNmdGxiVnnhZoltcXS7IFHzd4F6 NEfUVVUx6oDVNUCg{txoN22O NHS4UnM1QCCq NGH5UVJGSzVywrC9JFAvODF4INM1[{9uVA>? MUKyOVM2PjV4Nx?=
MDA-MB-231 NG\UVmZCeG:ydH;zbZMhSXO|YYm= M2PRVVAvOSEQvHevcWw> NGjmeVk1KGh? NEn2dXFqdmS3Y3XzJIFxd3C2b4Ppdy=> NIHjR3IzPTN3NkW2Oy=>
MDA-MB-231 NX72TmlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGwMlAyNzBwMEWg{txoN22O MoC3NlQhcA>? NEXJO|dqdmO{ZXHz[ZMhfGinIH\yZYN1cW:wIH;mJJN2[i2JMTDj[YxtKGSnYoLpdy=> NYf1cWVFOjV|NU[1Olc>
MDA-MB-231 MXTBdI9xfG:|aYOgRZN{[Xl? MlzFNE4xPeLCk{Gg{txoN22O NEDZdYozPCCq NFGyO|JqdmS3Y3XzJHBCWlBiKIDvcJkhSUSSLYLpZo9{\SCyb3z5cYVz[XOnLUGpJINt\WG4YXfl MoD4NlU{PTZ3Nke=
MDA-MB-231 NXni[W1wTnWwY4Tpc44hSXO|YYm= MYGw5qCUPTBizsznM41N M{S3WFI1KGh? MlO0bY5pcWKrdIOgeIhmKG[xcn3heIlwdiCxZjCzSEBidmRiMlSgZ49td26rZYO= NEn4PGYzPTN3NkW2Oy=>
A172 M3i0eWZ2dmO2aX;uJGF{e2G7 M13jNlExyqEQvHevcYw> NX7PT4U5PMLiaB?= Ml:4SG1UV8Li M2fVeZJme3WudIOgbY4hfGinIILleJJw\3KjZHWgeJJidnOyb4L0JI9nKG[udX;y[ZNk\W62IHfyZY52dGW| MX:yOVI{QTVyNx?=
KMS-6 NG\QPGdHfW6ldHnvckBCe3OjeR?= MYixxsDPxE4EoB?= NHjuR2gzPCCq NXexeZd7\XiqaXLpeJMhcGGuZjD0bIUhe2WlcnX0bY9vKG:oIHfhcIFvcW5vTFmgZZMh\GmmIITo[UBkd262cn;s MlnMNlUzOjlzMk[=
MEC MnTySpVv[3Srb36gRZN{[Xl? Ml36NUDPxE1? MY[xMlUhcA>? MXLjZZV{\XNiYTDkdoFu[XSrYzDk[YNz\WG|ZTDpckB1cGVic4Xy[oFk\SCYRVfGVlI> M2fidlI2OjJ6OEG1
HEK293/hERG MnLqSpVv[3Srb36gRZN{[Xl? NULabIJPOTEEoN88US=> NEn6epIyyqCq NXzGNIdsemW|dXz0d{BqdiCjIITpcYUu\GWyZX7k[Y51KHKnZIXjeIlwdiCvYYT1doUhcEWURzDwdo91\WmwwrC= MoGyNlUzOTh2Nkm=
RBE4 MVPBdI9xfG:|aYOgRZN{[Xl? M2K4dFLDqM7:TR?= NUHCSHp3O+LCk{K0xsBp MXTpcoR2[2W|IHHwc5B1d3OrczD0bY1mKGSncHXu[IVvfGy7 NWjrWHB6OjVzMkiwNlU>
RBE4 NImyeXpHfW6ldHnvckBCe3OjeR?= Mnj0NuKh|ryP M4X0OFPjiJN{NNMgbC=> M1XkNYlv[3KnYYPld{B1cGViWFLQNUBxem:2ZXnuJIxmfmWuczDh[pRmeiB|IHHu[EA3yqCqIH;mJJRz\WG2bXXueC=> MWiyOVEzQDB{NR?=
RBE4 MYTGeY5kfGmxbjDBd5NigQ>? M4fMcVLDqM7:TR?= MWez5qCUOjUEoHi= NVPtdGs5cW6lcnXhd4V{KGGldHn2[UBk[XOyYYPlMVEzKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVzyqB? M3vsbFI2OTJ6MEK1
RBE4 NGnsc2xHfW6ldHnvckBCe3OjeR?= MnLGNuKh|ryP NXvTOZdTO+LCk{K0xsBp NETkTWtqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDSU3MhfGmvZT3k[ZBmdmSnboTsfS=> MXuyOVEzQDB{NR?=
RBE4 NXi3[JpsTnWwY4Tpc44hSXO|YYm= Mk\2NuKh|ryP Mn3JN-KBmzJ2wrDo MULpcoR2[2W|IHGg[IVt[XmnZDDk[ZBt\XSrb36gc4YhfGinIFXSJGNiOiwEoHPvcpRmdnRiYYSgOuKhcCCxZjDpcoN2[mG2aX;uJJNq\26rZnnjZY51dHl? NF7yPXMzPTF{OECyOS=>
RBE4 M2K5RWZ2dmO2aX;uJGF{e2G7 M1PEd|LDqM7:TR?= MWqz5qCUOjUEoHi= NVrVRVh3cW6mdXPld{BidiCxdnXycI9i\CCxZjDDZVIsyqCrbjD0bIUhdWm2b3Poc45lemmjIHnuJJRp\SCoaYLzeEA3yqCqIH;mJIlv[3WkYYTpc44hMHEkgJm85qCKOC5yMEGpJIJ2fCCFYUKrxsBt\X[nbIOgbY4hfGirczDvdodidmWubHWg[IVkemWjc3XkJIFnfGW{IEGyxsBpKG:oIHnuZ5Vj[XSrb36= NWLXeYZPOjVzMkiwNlU>
Huh-7  MnjMSpVv[3Srb36gRZN{[Xl? NFfhNGoy|rypL33M MnzwN-KBmzJ2wrDo Ml\MbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCDUFWxJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NYLtcpVWOjVyMk[xO|Q>
HepG2  MXzGeY5kfGmxbjDBd5NigQ>? NF3XW3My|rypL33M M1W5WFPjiJN{NNMgbC=> NFzqXmxqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> Mn3xNlUxOjZzN{S=
H838-LKB1 MXjGeY5kfGmxbjDBd5NigQ>? NUXl[W1pOzEEoH7nM41t NUDkOldkOTJxMUigbC=> MWXpcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKEKrUNMg M4qwPVI2ODFzMEiy
H838-KDLKB1  MXnGeY5kfGmxbjDBd5NigQ>? NET0UlU{OMLibnevcYw> M1TqRlEzNzF6IHi= NIrwPZZqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIFLpVOKh NWC5PI5ROjVyMUGwPFI>
H838-KDLKB1  NYL5XWhnTnWwY4Tpc44hSXO|YYm= NUXGTWYxOzEEoH7nM41t NUGxXFNsOTJxMUigbC=> MXXpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyaH;zdIhwenmuYYTl[EBmUUZ{zsGgLJBpd3OyaH:t[WlHOs7zKR?= NUjjSoE4OjVyMUGwPFI>
3T3-L1 NX;sRXdyTnWwY4Tpc44hSXO|YYm= MnLVOUDPxGdxbXy= NFPQR4U{OCCvaX6= MorGcYlucWO|IITo[UBm\m[nY4TzJI9nKGmwc4XsbY4h[W6mIHPheZNmeyC{b3L1d5QheGixc4Doc5J6dGG2aX;uJI9nKEGtdDCoV4VzKDR5MzmgZY5lKHCqb4PwbI9zgWyjdHnvckBw\iCDU{G2NEApXGi{IE[0NkBidmRiU3XyJFU5QCl? MUKyOFg1Ozh{Nx?=
3T3-L1 NGD0PWZHfW6ldHnvckBCe3OjeR?= MXm1JO69\y:vbB?= MkS4N|AhdWmw NUDWPFdIemWlYYDpeJVt[XSnczDpcpN2dGmwIHHjeIlwdiC5aYToJJJme3CnY4SgeI8hemWpdXzheIlv\yCDa4SgZYN1cX[rdImgZY5lKEGVMU[wJJBpd3OyaH;yfYxifGmxbh?= Mln5NlQ5PDN6Mke=
3T3-L1 MnntSpVv[3Srb36gRZN{[Xl? NG\jRVE2KM7:Zz;tcC=> NU[xcG9NOzBibXnu M1X4ToNifXOnczDy[ZZmenOrYnzlJJJm\Gm|dILpZpV1cW:wIH;mJGdNXVR2 M3\oN|I1QDR|OEK3
3T3-L1 NI\YW|BHfW6ldHnvckBCe3OjeR?= NGK4UHg2KM7:Zz;tcC=> NUjHfJNSOcLiaB?= MojSZ4F2e2W|IILl[Il{fHKrYoX0bY9vKG:oIFfMWXQ1KGK3dDDuc5QhcW6lcnXhd4UhcW5iZ3z1Z49{\SC3cIThb4U> M3j5RVI1QDR|OEK3
3T3-L1 M{L1Z2Z2dmO2aX;uJGF{e2G7 NY\Ec21ZPSEQvHevcYw> M3v1clHDqGh? Mn7xZ4F2e2W|IIDoc5NxcG:{eXzheIlwdiCxZjD0bIUhTm:6T{GgeJJidnOlcnnweIlwdiCoYXP0c5I> MVOyOFg1Ozh{Nx?=
HeLa  M4PGeWZ2dmO2aX;uJGF{e2G7 NEXPcJE2KM7:Zz;tcC=> NVfmOmU2OyCq NXLNZnNw[2G3c3XzJI52[2ynYYKg[ZhkdHW|aX;uJI9nKHSqZTDGc5hQOSC2cnHud4NzcXC2aX;uJIZi[3SxcjDhcoQh\GWlcnXhd4V{KHS{YX7zZ5JqeHSrb36gc4YhTm:6T{GtdoVofWyjdHXkJIdmdmW| M3:4R|I1QDR|OEK3
HEK293 MXPGeY5kfGmxbjDBd5NigQ>? NEns[|A2yqEQvHevcYw> NXrYb4RnOTMEoHi= NVL1TnFN[WKxbHnzbIV{KEOPQT3pcoR2[2WmIFPSSWxFOiC|ZXPy[ZRqd25? M{XydlI1Pjh5NEOx
COS-1 MlfWSpVv[3Srb36gRZN{[Xl? NH\hbno2KML3Zz;tcC=> MlHINlQhcMLi MWry[ZN1emmldIOgcI9k[WyrenH0bY9vKG:oIF7CJIlvKHSqZTDw[ZJqdnWlbHXhdkBz\Werb39CpC=> NWWy[3o6OjR4N{G3OVE>
PRP NWSyWoRZTnWwY4Tpc44hSXO|YYm= NE\TUokyOCEQvF2= MXLhZpJw\2G2ZYOgV2RHNTIQsT3t[YRq[XSnZDDDXGNTPyCneITldo5idGm8YYTpc47DqA>? M2LUWlI1PjZ6N{Ww
RAW264.7 MU\BdI9xfG:|aYOgRZN{[Xl? NEHOPY81KM7:TR?= M3LVUlQ5KGh? NFn3c4ZifHSnboXheIV{KHSqZTDpcohq[mm2aX;uJI9nKG:6LVzEUE1qdmS3Y3XkJIFxd3C2b4Ppd{BidmRidHjlJIZi[2muaYTheIlwdiCxZjDjbI9t\XO2ZYLvcEBm\m[udYigZpkhSWNvaFWtNVhCNU6KMh?= MX:yOFY{QTB|Mh?=
MDMs MUTBdI9xfG:|aYOgRZN{[Xl? NX7hTZltOTEkgJpOwIcwdWx? M{nPVVEzNzF3IHi= MVzpcoR2[2W|IHHwc5B1d3Orcx?= Mmi5NlQ2PTZ4OUW=
PMHs  Mmf1SpVv[3Srb36gRZN{[Xl? NGXRcHYyOOLCk{Kw5qCK|rypL33s M3H6ZlI16oDLaB?= MlOxSG1UVw>? NXj0ZZJtcW6mdXPl[EBGWiC|dILld5M> NUm3No5WOjR2MEeyOFI>
PMHs  NG\E[o9CeG:ydH;zbZMhSXO|YYm= M1THSlEx6oDVMkFihKnPxGdxbXy= NEDoW3YzPOLCiXi= MkPRSG1UVw>? NIDzSHRqdmO{ZXHz[ZMh[2WubDDk[YF1cA>? NWTwT4dXOjR2MEeyOFI>
HEK293/tau NVH3SHpFTnWwY4Tpc44hSXO|YYm= MY[1JO69VQ>? NGXxOFkyNzJxNDDo MlH4bY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA> MVqyOFM3QDB6OR?=
HEK293/tau NFi0T|VHfW6ldHnvckBCe3OjeR?= Ml7TOUDPxE1? M1f4VlMhcA>? NEf2dWhqdmS3Y3XzJJRifSCqeYDldpBpd3OyaH;yfYxifGmxbh?= NH;ZcogzPDN4OEC4PS=>
ADF NGTVTJFHfW6ldHnvckBCe3OjeR?= MnnVNVAh|ryP NYXKeXRVOTZiaB?= NHTFVWJqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? M1vhXFI1OjJ6MkOy
U373  NVnlRmQ{TnWwY4Tpc44hSXO|YYm= Mli5NVAh|ryP MlPsNVYhcA>? MlPsbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NGnJUWgzPDJ{OEKzNi=>
RKO-HIPK2i NVmzTodsTnWwY4Tpc44hSXO|YYm= MYOxNEDPxE1? MUWxOkBp M2jyeolvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV MorTNlQzOjh{M{K=
ADF  MXHGeY5kfGmxbjDBd5NigQ>? NH3Jd2gyOCEQvF5CpC=> M2nJSFYhcA>? NIfCemJqdXCjaYLzJJRp\SCGQzDhZ5RqfmG2aX;u MXOyOFIzQDJ|Mh?=
Huh7 M2PHVWZ2dmO2aX;uJGF{e2G7 MWm1JO69\y:vbB?= M3rKeFQhcA>? MX3hZo9tcXOqZYOgeIhmKHOnY4LleIlwdiCxZjCgbY51emGlZXzseYxieiCDcH;C M3vGbVI1OTByMUSw
Huh7 MYHGeY5kfGmxbjDBd5NigQ>? MU[1JO69\y:vbB?= NI\qenIyKGh? M2OxRYNifXOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIFHwc2Iu[3Knc3PlcpR{ MVyyOFExODF2MB?=
Huh7 NE\vfW5HfW6ldHnvckBCe3OjeR?= M2LQTVXjiJNzMNMgcocwdWx? NH\VZnQyOiCq MYXpcoNz\WG|ZYOgRZBwSi2lcnXzZ4VvfHNid3n0bI92fCCrbnjpZol1cW6pIIPlZ5JmfGmxbh?= Mon5NlQyODBzNEC=
BAECs MkPjSpVv[3Srb36gRZN{[Xl? MYm1JO69\y:vbB?= Mn\yNE01KGh? NUGwZ49JcW6mdXPld{B1cGVicnHwbYQh\GWyaH;zdIhwenmuYYTpc44hd2ZiZV7PV{BifCCVZYKxNVc6 NHjscWEzPDB6NUKyOS=>
Macrophages MUDGeY5kfGmxbjDBd5NigQ>? NEe4U2Q4OSEEtV2= MV22JIg> NH\3S|ZqdmirYnn0d{BtfW6jc3nuJIlvfGW{bnHsbZpifGmxbtMg MmjaNlQxOzl5NEC=
Colo 205 M3HXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nl[VAuPSEQvHevcWw> NV:zbHhRPDhiaB?= NEfZS45qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDzeZNx\W6|aX;uJIN2dHS3cnXzJJdqfGhiYX6g[ZN1cW2jdHXkJGlEPTBib3[gglE2KG6pL33M NUfDfVhjOjN7N{O5PVY>
Colo 205 NV\2eFZETnWwY4Tpc44hSXO|YYm= NIrJOJIxNjBzMj2wMlAzPSEQvHevcWw> Ml7zNVQh\A>? M2jqcJJm\HWlZYOgeIhmKGOub37v[4VvcWOrdImgc4YhS2:ubzCyNFUhS1OFcx?= MmfmNlM6PzN7OU[=
Colo 205 MXjBdI9xfG:|aYOgRZN{[Xl? NYfUV5RJOC5zIN88[{9uVA>? MmW2NE0zPCCq NUTPW5hicW6mdXPld{BieG:ydH;zbZMhd2ZiQ3;sc{AzODViY3XscJMhcW5ic4XzdIVve2mxbjDjeYx1fXKncx?= NELkbmwzOzl5M{m5Oi=>
Colo 205 NHz3WYtHfW6ldHnvckBCe3OjeR?= M1HHZlAvODF3IN88[{9uVA>? M2G2TFI1KGh? MV7pcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFXSJJN1emW|cz3y[YxifGWmIHflcoV{ MUSyN|k4Ozl7Nh?=
Colo 205 MWfGeY5kfGmxbjDBd5NigQ>? NF;CVocxNjBzNTFOwIcwdUx? MoHzNlQhcA>? M1fPRolvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXB{ NEXJOmkzOzl5M{m5Oi=>
IBRS2 MXrGeY5kfGmxbjDBd5NigQ>? MWG1JO69\y:vbB?= MkjMNE42KGh? NI[xOJRFVVOR NELjc4JlcXO{dYD0d{B1cGViRWLHTWMh[W6mIFfvcIdqyqB? MY[yN|k3OzV|NB?=
IBRS2 M{H1VmZ2dmO2aX;uJGF{e2G7 NF7MU202KM7:Zz;tcC=> NVLqV3l2OC53IHi= Mo\ySG1UVw>? NEX0[phmdmijbnPld{BHVUSYIHnu[oVkfGmxbh?= M4jx[FI{QTZ|NUO0
HeLa NF7UNJFHfW6ldHnvckBCe3OjeR?= NYLPT5BlOiEQvF2= MlnwNkBpyqB? M{DtWoF1fGWwdXH0[ZMhfGinIGTOSk1qdmS3Y3XkJJNm[3KndHnvckBw\iCLTD2xOS=> M1:1VVI{QTVyOEmy
HFS  NFyzc2lHfW6ldHnvckBCe3OjeR?= MkPpNE0yKM7:Zz;tcC=> NEDVUY4zPCCq NImwZlRIVFSSIHX4dJJme3Orb36gdoVi[2inczDhJJBt[XSnYYWgZZQh[2:wY3XueJJifGmxboOgZZMhdG:5IHHzJFAvODFiwsXnM41t NF;jeIMzOzh7NE[zNy=>
HFS  M2PkNGZ2dmO2aX;uJGF{e2G7 M131SVAvODFiwsXnM41t MXGyOEBp Mnj1bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIdtgWOxc4DobY5od2yrcHnkJJN6dnSqYYPlJIdmdmW|IHH0JFYhcA>? NUPoV5RjOjN6OUS2N|M>
OVCAR-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHZNWIy6oDVMUZCpO69VcLi MUCyOOKhcA>? MmPPbY5lfWOnczDhJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgcLi NF\QOVUzOzh{Nkm2OC=>
OVCAR-3 NFr4NmRHfW6ldHnvckBCe3OjeR?= NVOxenB[OeLCk{G1xsDPxE4EoB?= MoP5NlTDqGh? NFTROWZqdmS3Y3XzJI52[2ynYYKg[IFu[Wen NI[1cGwzOzh{Nkm2OC=>
OVCAR-3 M3TCU2Fxd3C2b4Ppd{BCe3OjeR?= MXKxMVExyqEQvF2= MoXlOEBp NIS1PHNqdmS3Y3XzJJRp\SCjY4TpeoF1cW:wIH;mJIFxd3C2b4Ppd{1z\WyjdHXkJJBzd3SnaX7z MVmyN|gzPjl4NB?=
OVCAR-3 NWPCWFNtSXCxcITvd4l{KEG|c3H5 MXmxNOKh|ryP NVu4TJRROjUEoHi= M4n0Zolv\HWlZYOgZYN1cX[jdHnvckBw\iClYYPwZZNmew>? M3TMTlI{QDJ4OU[0
OVCAR-3 Mn3CSpVv[3Srb36gRZN{[Xl? M1rJWVHjiJNzMNMg{txO Mlf6NlTDqGh? M3mwSYlv\HWlZYOg[Il{enWydHnvckBw\iC2aHWgcYl1d2Oqb37kdolidCC2cnHud41mdWK{YX7lJJBwfGWwdHnhcC=> MoLYNlM5OjZ7NkS=
OVCAR-3 NHe3TldHfW6ldHnvckBCe3OjeR?= NWrYSGYyOeLCk{GwxsDPxE1? MXyyOOKhcA>? Ml:4bY5lfWOnczDmc5Ju[XSrb36gc4YhemWjY4TpeoUhd3i7Z3XuJJNx\WOrZYO= M3nKVVI{QDJ4OU[0
OVCAR-3 MmS5SpVv[3Srb36gRZN{[Xl? M2j1RVHjiJNzMNMg{txO MlfPNlTDqGh? MXfpcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= M2\Fd|I{QDJ4OU[0
MKN45 M3\v[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmwW|V1UUN3MEywMlAxOSEQvHevcYw> NWO4V2lLOjN5OUOzOFI>
LOVO M{Cyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jMbWlEPTB;MD6xNkDPxGdxbXy= NVLoWnZWOjN5OUOzOFI>
A549 NFHibm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7DUHJKSzVyPUCuNFQh|rypL33s MWSyN|c6OzN2Mh?=
MDA-MB-435 M{TZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XMc2lEPTB:MD6wNFEh|rypL33s MVSyN|c6OzN2Mh?=
HepG2 M3Xrdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRDBwMECxJO69\y:vbB?= NXzLS|lXOjN5OUOzOFI>
HL-60 Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS1TWM2ODxyLkCwNUDPxGdxbXy= NEfHSnAzOzd7M{O0Ni=>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[5]
+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method: HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID